Skip to content
Beacon

OZEMRoundhill Glp-1 & Weight Loss ETF

Grow my money#1803 of 2944 for Grow my money

Seeks to provide capital appreciation.

Roundhill Investments · Since 2024 (1 year)

Annual Cost

0.59%

#2801 out of 5,332 ETFs

Fund Size

$51M

#3326 out of 5,332 ETFs

Dividend Yield

1.32%

Track Record

1 year

#3672 out of 5,332 ETFs

Performance

1 Year

+25.7%

3 Years

N/A

5 Years

N/A

What's inside

Asset class
Strategy
active selection
Cap
multi cap
Focus
Obesity & GLP-1

Asset allocation

Stocks
99.2%
Other
0.5%
Cash
0.3%

Sector breakdown

Healthcare
100.0%

Top holdings

Eli Lilly and CoLLY16.1%
Novo Nordisk AS ADRNVO13.1%
Pfizer IncPFE7.6%
Viking Therapeutics IncVKTX5.3%
Innovent Biologics Inc1801.HK5.1%
Ascletis Pharma Inc Ordinary Shares1672.HK4.7%
Amgen IncAMGN3.9%
Roche Holding AG Ordinary Shares newROP.SW3.9%
AstraZeneca PLCAZN.L3.8%
Hanmi Pharm Co Ltd128940.KS3.7%

Risk profile

Volatility (1Y)

25.2%

High

Max drawdown

-28.6%

Worst peak-to-trough loss

Sharpe (3Y)

N/A

Sortino (3Y)

N/A

Similar ETFs

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

Thematic ETF — launched after the rally

Thematic funds are typically launched after a theme has delivered its strong returns. Morningstar's 2024 Global Thematic Funds Landscape finds that only about 1 in 10 thematic funds have survived and beaten a broad global equity benchmark over the past 15 years — roughly 60% have been closed outright. The narrative is always compelling; the track record rarely is.

Source: Morningstar, 'Global Thematic Funds Landscape' (2024)

Why we flagged this: Narrow thematic name, launched in the last 3 years, $51M in assets (under our $500M threshold).

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

Data updated on 2026-05-05